Inclusion Criteria

Inclusion criteria:

1. Pathologically confirmed stage IIIB/IV adenocarcinoma in non-small cell lung
cancer[NSCLC]

2. Progressive disease following a second-line cytotoxic chemotherapy including at least
one platinum-containing regimen

3. A known wild-type EGFR status

4. Patients 18 years of age or older

Exclusion criteria:

1. More than two prior cytotoxic chemotherapy treatment regimens for relapsed or
metastatic disease

2. Prior treatment with EGFR targeting small molecules or antibodies

3. Radiotherapy or surgery within 4 weeks prior to study entry

4. Active brain metastasis

5. Known pre-existing interstitial lung disease

6. History or presence of clinically relevant cardiovascular abnormalities

7. Cardiac left ventricular function with resting ejection fraction of less than 50%

8. Absolute neutrophil count[ANC] < 1,500/mm3

9. Platelet count <100,000/mm3

10. Creatinine clearance<60ml/min or serum creatinine >1.5 times upper limit of normal

11. Women of childbearing potential, or men who are able to father a child, unwilling to
use a medically acceptable method of contraception during the trial

12. Pregnancy or breast-feeding